

Ontario Public Drug Programs

Drug Submission Status

Report for June 2016

Complete Streamlined Multiple-Source

Submissions for Future Formulary Listing

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for listing on the Ontario Drug Benefit Formulary. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be listed as benefits in a future Formulary update. Final listing status will be communicated when the Formulary update is published on the Ministry website and via an OPDP Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Generic Medical Partners Inc.	Med-Solifenacin	Vesicare	solifenacin succinate	5mg	FC tablet	02428911
Generic Medical Partners Inc.	Med-Solifenacin	Vesicare	solifenacin succinate	10mg	FC tablet	02428938
Jamp Pharma Corporation	Jamp-Duloxetine	Cymbalta	duloxetine HCl	30mg	DR capsule	02451913
Jamp Pharma Corporation	Jamp-Duloxetine	Cymbalta	duloxetine HCl	60mg	DR capsule	02451921

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Natco Pharma Inc.	Nat-Granisetron	Kytril	granisetron HCl	1mg	FC tablet	02452359
Sanis Health Inc.	Amlodipine	Norvasc	amlodipine besylate	5mg	tablet	02331284
Sanis Health Inc.	Amlodipine	Norvasc	amlodipine besylate	10mg	tablet	02331292
Sanis Health Inc.	Sertraline	Zoloft	sertraline HCl	100mg	capsule	02353547